文献速递乳腺癌

含长多表位肽E75-AE36与PADRE的纳米脂质体疫苗在TUBO乳腺癌小鼠模型中诱导有效免疫应答

Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
PubMed 文献 · Eur J Cancer · 2020-03-04

该研究在HER2阳性TUBO乳腺癌小鼠模型中,比较了含短肽AE36与E75混合、长多表位肽E75-AE36及联合PADRE的脂质体疫苗经皮下注射的预防与治疗效果。结果显示,长肽脂质体联合PADRE可 superior 诱导CD4+和CD8+ T细胞应答并显著增强IFN-γ产生,明显抑制肿瘤生长并延长生存期。提示该多表位脂质体疫苗可能作为乳腺癌候选肽疫苗。

要点

  • 长多表位肽E75-AE36脂质体联合PADRE较短肽或非脂质体方案更强诱导CD4+/CD8+ T细胞应答。
  • 该联合方案显著增强IFN-γ产生,并明显抑制TUBO小鼠肿瘤生长、延长生存期。
  • 结果支持其作为HER2阳性乳腺癌预防/治疗性多表位肽疫苗候选。

核心结论

  • 含长多表位肽E75-AE36与PADRE的脂质体疫苗可在TUBO乳腺癌小鼠中诱导强抗原特异性CD8+ T细胞免疫应答,并可能作为乳腺癌候选肽疫苗。

研究设计与样本

  • 在HER2阳性TUBO荷瘤小鼠中,经系列皮下注射比较含短肽AE36与E75混合、长多表位肽E75-AE36及联合PADRE的脂质体疫苗,设预防与治疗模型。

主要发现

  • 长肽脂质体联合PADRE较脂质体短肽及非脂质体肽方案更优诱导CD4+和CD8+ T细胞应答。
  • 长肽脂质体联合PADRE显著增强IFN-γ产生。
  • 长肽脂质体联合PADRE明显抑制小鼠肿瘤生长并延长生存期。

临床怎么用

  • 结果支持进一步评估含长多表位肽E75-AE36与PADRE的脂质体疫苗作为乳腺癌预防/治疗性肽疫苗候选。

局限性

  • 证据来自小鼠TUBO乳腺癌模型,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The main goal of peptide-based cancer vaccines is to induce the immune system and activation of effective T cell responses against cancerous cells. Nevertheless, the potency of peptide vaccines is insufficient in most of cases and had limited clinical success. Therefore, the optimization of peptide-based cancer vaccine is essential to achieve powerful therapeutic outcomes. One strategy to enhanced potency of peptide vaccines and induce strong immune responses is the preparation of multi-epitope peptide formulation containing both Th- and cytotoxic T lymphocyte-induced responses epitope using suitable delivery system. For this reason, we studied the effect of Dioleoylphosphatidylethanolamine-containing liposomal vaccine composed of a mixture of short peptides AE36 and E75 (HER2/neu-derived peptides) and long multi-epitope peptide E75-AE36 (linkage of short peptides) in combination with a Pan HLA-DR epitope (PADRE) peptide. These formulations were examined using a series of subcutaneously injection to HER-2+ TUBO-tumoured mice in prophylactic and therapeutic model. We observed that mice vaccinated with liposomal long peptide in combination with PADRE resulted in the superior induction of CD4+ and CD8+ T cells responses and significantly enhanced production of IFN-γ compared with liposomal short peptides and non-liposomal peptides formulations. Moreover, liposome-long peptide with PADRE led to the considerable reduction of tumour growth and lifespan induction in mouse model. In conclusion, our study indicated that liposomal formulation containing long multi-epitope peptide E75-AE36 with PADRE could be used as an effective multi-epitope prophylactic/therapeutic vaccine to generate potent antigen-specific CD8+ T-cell immune response and may be introduced as a possible candidate peptide vaccine for breast cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zamani P, Teymouri M, Nikpoor AR, et al. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer. Eur J Cancer. 2020. PMID: 32145473. doi:10.1016/j.ejca.2020.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。